U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 13:34:27 GMT 2023
Edited
by admin
on Sat Dec 16 13:34:27 GMT 2023
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
Z20OC92TDI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZANIDATAMAB
USAN   INN  
Official Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Common Name English
ZW-25
Code English
Zanidatamab [WHO-DD]
Common Name English
ANTI-HER2 BI-SPECIFIC MONOCLONAL ANTIBODY ZW25
Common Name English
ZANIDATAMAB [USAN]
Common Name English
zanidatamab [INN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 LIGHT CHAIN VARIABLE REGION FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 20-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN-MUS MUSCULUS BIPARA
Common Name English
ZW25
Code English
Classification Tree Code System Code
NCI_THESAURUS C155711
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
NCI_THESAURUS C28227
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
FDA ORPHAN DRUG 715119
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
FDA ORPHAN DRUG 554716
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
FDA ORPHAN DRUG 519516
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
Code System Code Type Description
USAN
HI-248
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
FDA UNII
Z20OC92TDI
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
DRUG BANK
DB15471
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
NCI_THESAURUS
C130010
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
INN
10997
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
CAS
2169946-15-8
Created by admin on Sat Dec 16 13:34:27 GMT 2023 , Edited by admin on Sat Dec 16 13:34:27 GMT 2023
PRIMARY
From To
1_24 1_89
1_150 1_224
1_261 2_229
1_264 2_232
1_296 1_356
1_402 1_460
2_23 2_97
2_147 2_203
2_223 3_215
2_264 2_324
2_370 2_428
3_24 3_89
3_135 3_195
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_332
N 2_300
Related Record Type Details
ZANIDATAMAB ZOVODOTIN
CONJUGATE -> PARENT
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
TARGET -> INHIBITOR
BINDING
Related Record Type Details
ZANIDATAMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966